Document is current
Any future updates will be listed below
-
Authors
van der Zeeuw, S. L. https://orcid.org/0009-0001-2000-6763
van Tilburg, S. J. https://orcid.org/0000-0003-3983-9797
Jacobs, B. C. https://orcid.org/0000-0002-8985-2458
Koch, B. C. P. https://orcid.org/0000-0002-1202-3643
Dalm, V. A. S. H. https://orcid.org/0000-0001-5945-4435
Crombag, M. B. S. https://orcid.org/0000-0002-2241-252X
Preijers, T. https://orcid.org/0000-0001-6953-0358
- License Information
-
More Information
Article History
Received: 31 October 2025
Accepted: 29 March 2026
First Online: 26 May 2026
Declarations
:
: SZ, MC, and TP have no competing interests to declare. ST received funding for research from Octapharma (all paid to institution). VASHD received funding for research from Takeda, CSL Behring, Pharming and Moderna (all paid to institution), and honoraria for lectures from AstraZeneca, Pfizer, Pharming, Takeda, CSL Behring and Johnson & Johnsons (all paid to institution). BCJ received funding for research from Sanquin, Grifols, Octapharma and CSL-Behring (all paid to institution). BK is an Editorial Board member of Clinical Pharmacokinetics and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Conceptualisation: Shannon van der Zeeuw, Sander van Tilburg, Tim Preijers; Methodology: Shannon van der Zeeuw, Sander van Tilburg, Tim Preijers; Formal analysis and investigation: Shannon van der Zeeuw, Sander van Tilburg; Writing – original draft preparation: Shannon van der Zeeuw, Sander van Tilburg, Tim Preijers; Writing – review and editing: Shannon van der Zeeuw, Sander van Tilburg, Rose Crombag, Birgit Koch, Virgil Dalm, Tim Preijers, Bart Jacobs; Funding acquisition: none; Resources: Shannon van der Zeeuw, Sander van Tilburg; Supervision: Rose Crombag, Birgit Koch, Virgil Dalm, Tim Preijers, Bart Jacobs.
